

Quynh-Thu Le

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4158845/publications.pdf>

Version: 2024-02-01

165
papers

11,384
citations

46918

47
h-index

31759

101
g-index

169
all docs

169
docs citations

169
times ranked

12375
citing authors

#	ARTICLE	IF	CITATIONS
1	International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2023, 84, 307-319.	0.4	10
2	Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. <i>European Journal of Cancer</i> , 2022, 162, 221-236.	1.3	22
3	An International Consensus on the Design of Prospective Clinicalâ€“Translational Trials in Spatially Fractionated Radiation Therapy. <i>Advances in Radiation Oncology</i> , 2022, 7, 100866.	0.6	7
4	Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2022, 83, .	0.4	0
5	De-escalating elective nodal irradiation for nasopharyngeal carcinoma. <i>Lancet Oncology</i> , The, 2022, 23, 441-443.	5.1	0
6	Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 787-795.	0.4	6
7	The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF- κ B signaling. <i>Science Advances</i> , 2022, 8, eabh2445.	4.7	10
8	JUPITERâ€“02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps. <i>Cancer Communications</i> , 2022, 42, 56-59.	3.7	6
9	Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA. <i>Nature Methods</i> , 2022, 19, 759-769.	9.0	42
10	Aldehyde dehydrogenase 3A1 deficiency leads to mitochondrial dysfunction and impacts salivary gland stem cell phenotype. , 2022, 1, .		0
11	The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer. <i>Cancer Research Communications</i> , 2022, 2, 725-738.	0.7	5
12	Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 604-615.	2.9	16
13	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , 2021, 12, 117.	5.8	34
14	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2021, 39, 840-859.	0.8	178
15	Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). <i>Journal of Clinical Oncology</i> , 2021, 39, 956-965.	0.8	195
16	Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors. <i>Radiotherapy and Oncology</i> , 2021, 156, 201-208.	0.3	14
17	Evaluation of Oncology Trial Results Reporting Over a 10-Year Period. <i>JAMA Network Open</i> , 2021, 4, e2110438.	2.8	15
18	Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores â€“ A pooled analysis of RTOG 0129 and 0522. <i>Oral Oncology</i> , 2021, 116, 105241.	0.8	6

#	ARTICLE	IF	CITATIONS
19	Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 727-736.	5.1	45
20	NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2882.	1.7	6
21	Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
22	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.4	42
23	Reply to A. J. Cmelak et al and B. Kalra et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 2734-2735.	0.8	0
24	Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. <i>Cell Chemical Biology</i> , 2021, 28, 1206-1220.e6.	2.5	19
25	Cost-Effectiveness of Nasopharyngeal Carcinoma Screening With Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide. <i>Journal of the National Cancer Institute</i> , 2021, 113, 852-862.	3.0	26
26	Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: A secondary analysis of NRG Oncology RTOG 0129 and 0522. <i>Head and Neck</i> , 2021, 44, 158.	0.9	3
27	Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 327-336.	2.8	27
28	Proton radiotherapy and treatment delay in head and neck squamous cell carcinoma. <i>Laryngoscope</i> , 2020, 130, E598-E604.	1.1	6
29	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.3	24
30	Predictive classifier for intensive treatment of head and neck cancer. <i>Cancer</i> , 2020, 126, 5263-5273.	2.0	11
31	Lysosomal trafficking mediated by Arl8b and BORG promotes invasion of cancer cells that survive radiation. <i>Communications Biology</i> , 2020, 3, 620.	2.0	21
32	Rab27b contributes to radioresistance and exerts a paracrine effect via epiregulin in glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa091.	0.4	8
33	Pilot study of loss of the p53/p63 target gene PERP at the surgical margin as a potential predictor of local relapse in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2020, 42, 3188-3196.	0.9	4
34	De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies. <i>Journal of Clinical Oncology</i> , 2020, 38, 2552-2557.	0.8	58
35	Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 160, 1331-1345.e1.	0.4	16
36	The role of Glial cell derived neurotrophic factor in head and neck cancer. <i>PLoS ONE</i> , 2020, 15, e0229311.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 766-778.	0.4	70
38	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. International Journal of Radiation Oncology Biology Physics, 2020, 107, 618-627.	0.4	156
39	Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations. Clinical Cancer Research, 2020, 26, 2972-2985.	3.2	9
40	18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002.. Journal of Clinical Oncology, 2020, 38, 6563-6563.	0.8	3
41	Comments on the Publication by Corkum etÂal on "Does 5 + 5Âmm Equal Better Radiation Treatment Plans in Head and Neck Cancers?" Advances in Radiation Oncology, 2020, 5, 140-141.	0.6	0
42	Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer. Clinical Cancer Research, 2019, 25, 7078-7088.	3.2	21
43	Lambda-Carrageenan Enhances the Effects of Radiation Therapy in Cancer Treatment by Suppressing Cancer Cell Invasion and Metastasis through Racgap1 Inhibition. Cancers, 2019, 11, 1192.	1.7	9
44	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. Oral Oncology, 2019, 95, 106-114.	0.8	18
45	Radiographic Extranodal Extension in Human Papillomavirus-Associated Oropharyngeal Carcinoma: Can it Help Tailor Treatment?. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1028-1029.	0.4	3
46	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 567-580.	0.4	96
47	Nasopharyngeal carcinoma. Lancet, The, 2019, 394, 64-80.	6.3	1,667
48	The changing therapeutic landscape of head and neck cancer. Nature Reviews Clinical Oncology, 2019, 16, 669-683.	12.5	454
49	Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2019, 104, 942-952.	0.4	23
50	Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2019, 37, 1578-1589.	0.8	50
51	Cost-effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States. Otolaryngology - Head and Neck Surgery, 2019, 161, 82-90.	1.1	8
52	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. Journal of the National Cancer Institute, 2019, 111, 655-663.	3.0	56
53	Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG) Tj ETQq1 1 0,784314 r&BT /Over 0.3 879	0.3	879
54	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer, 2019, 125, 382-390.	2.0	14

#	ARTICLE	IF	CITATIONS
55	Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx. <i>Cancer</i> , 2019, 125, 704-711.	2.0	18
56	Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. <i>Journal of Clinical Investigation</i> , 2019, 129, 5553-5567.	3.9	94
57	NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6023-6023.	0.8	6
58	Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6065-6065.	0.8	15
59	Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6073-6073.	0.8	19
60	Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6010-6010.	0.8	2
61	A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1 β -XBP1 Activation. <i>Molecular Cancer Research</i> , 2018, 16, 745-753.	1.5	8
62	Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. <i>Radiotherapy and Oncology</i> , 2018, 126, 3-24.	0.3	244
63	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 126, 25-36.	0.3	214
64	Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 1143-1169.	0.8	216
65	Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results Medicare analysis. <i>Cancer</i> , 2018, 124, 4486-4494.	2.0	28
66	Focus on the Number of Radiation Oncology Trials or on Clinical Relevance? Reply. <i>JAMA Oncology</i> , 2018, 4, 1791.	3.4	1
67	Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 10756-10761.	3.3	121
68	Adaptive radiotherapy for head and neck cancer: Are we ready to put it into routine clinical practice?. <i>Oral Oncology</i> , 2018, 86, 19-24.	0.8	16
69	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , 2018, 4, 1073.	3.4	44
70	Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 6279-6284.	3.3	23
71	Feasibility of optimizing intensity-modulated radiation therapy plans based on measured mucosal dose adjacent to dental fillings and toxicity outcomes. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 444-452.	0.8	0
72	In Regard to Beadle and Anderson. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 229-230.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.. Journal of Clinical Oncology, 2018, 36, 6010-6010.	0.8	28
74	A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG.. Journal of Clinical Oncology, 2018, 36, 6050-6050.	0.8	12
75	Robust Estimation of Electron Density From Anatomic Magnetic Resonance Imaging of the Brain Using a Unifying Multi-Atlas Approach. International Journal of Radiation Oncology Biology Physics, 2017, 97, 849-857.	0.4	11
76	Chemical Space Mimicry for Drug Discovery. Journal of Chemical Information and Modeling, 2017, 57, 875-882.	2.5	63
77	Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	85
78	Very high-energy electron (<sc>VHEE</sc>) beams in radiation therapy; Treatment plan comparison between <sc>VHEE</sc> , <sc>VMAT</sc> , and <sc>PPBS</sc>. Medical Physics, 2017, 44, 2544-2555.	1.6	54
79	Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2017, 98, 775-783.	0.4	9
80	Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. International Journal of Radiation Oncology Biology Physics, 2017, 98, 996-1001.	0.4	73
81	Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. Radiotherapy and Oncology, 2017, 125, 338-343.	0.3	29
82	In Reply to Zoto Mustafayev and Ozyar. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1307.	0.4	2
83	Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. Oral Oncology, 2017, 71, 180-183.	0.8	7
84	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. International Journal of Radiation Oncology Biology Physics, 2017, 97, 687-699.	0.4	35
85	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. International Journal of Radiation Oncology Biology Physics, 2017, 97, 667-677.	0.4	30
86	The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited. Cancer, 2017, 123, 12-16.	2.0	8
87	Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. JCO Precision Oncology, 2017, 2017, 1-9.	1.5	6
88	A randomized phase II study of chemoradiation (CRT) +/- nivolumab (Nivo) with sequential safety evaluations of Nivo +/- lirilumab (Liri) or ipilimumab (Ipi) concomitant with (C) RT in intermediate (IR) and high-risk (HR) head and neck squamous cell carcinoma (HNSCC) (RTOG 3504, NCT02764593).. Journal of Clinical Oncology, 2017, 35, TPS6097-TPS6097.	0.8	4
89	Prognostic value of midtreatment FDG- β PET in oropharyngeal cancer. Head and Neck, 2016, 38, 1472-1478.	0.9	29
90	Design and rationale of a prospective, multi-institutional registry for patients with sinonasal malignancy. Laryngoscope, 2016, 126, 1977-1980.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Proposal for the 8th edition of the <sc>AJCC</sc>/<sc>UICC</sc> staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. <i>Cancer</i> , 2016, 122, 546-558.	2.0	254
92	Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours. <i>Scientific Reports</i> , 2016, 6, 31146.	1.6	36
93	Flexible radioluminescence imaging for FDGâ€guided surgery. <i>Medical Physics</i> , 2016, 43, 5298-5306.	1.6	7
94	Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 362-371.	0.4	22
95	Neurotrophic Factors and Their Potential Applications in Tissue Regeneration. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2016, 64, 89-99.	1.0	65
96	Nuclear repartitioning of galectin-1 by an extracellular glycan switch regulates mammary morphogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E4820-7.	3.3	63
97	Identification of Doxorubicin as an Inhibitor of the IRE1â€XBP1 Axis of the Unfolded Protein Response. <i>Scientific Reports</i> , 2016, 6, 33353.	1.6	27
98	Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensityâ€modulated radiotherapy. <i>Cancer</i> , 2016, 122, 3307-3315.	2.0	125
99	Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). <i>Radiotherapy and Oncology</i> , 2016, 119, 454-460.	0.3	27
100	Acridine Derivatives as Inhibitors of the IRE1â€XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2055-2065.	1.9	24
101	Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: TheÂRTOG Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1346-1354.	0.4	28
102	Botulinum Toxin Confers Radioprotection in Murine Salivary Glands. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1190-1197.	0.4	21
103	Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 617-625.	3.3	26
104	Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6024-6024.	0.8	2
105	Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8510-8510.	0.8	0
106	A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers. <i>Oral Oncology</i> , 2015, 51, 1132-1137.	0.8	16
107	Individualizing treatment for patients with nasopharyngeal cancer. <i>Cancer</i> , 2015, 121, 2671-2673.	2.0	2
108	Emerging Treatment Paradigms in Radiation Oncology. <i>Clinical Cancer Research</i> , 2015, 21, 3393-3401.	3.2	33

#	ARTICLE	IF	CITATIONS
109	Institutional Clinical Trial Accrual Volume and Survival of Patients With Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 156-164.	0.8	216
110	Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 568-576.	0.4	75
111	Reply to B. O'Sullivan et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1708-1709.	0.8	11
112	Metabolic Tumor Volume as a Prognostic Imaging-Based Biomarker for Head-and-Neck Cancer: Pilot Results From Radiation Therapy Oncology Group Protocol 0522. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 721-729.	0.4	64
113	Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1044-1052.	0.4	61
114	Survival benefit for adjuvant radiation therapy in minor salivary gland cancers. <i>Oral Oncology</i> , 2015, 51, 438-445.	0.8	20
115	Long-Term Results of Radiation Therapy Oncology Group 9903: A Randomized Phase 3 Trial to Assess the Effect of Erythropoietin on Local-Regional Control in Anemic Patients Treated With Radiation Therapy for Squamous Cell Carcinoma of the Head and Neck. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 907-915.	0.4	22
116	$\hat{\gamma}^2$ -Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1458-1464.	2.8	14
117	Overview of Advances in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3225-3226.	0.8	39
118	The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- chemotherapy in locally advanced (LA) head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 6003-6003.	0.8	9
119	Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6011-6011.	0.8	5
120	Effect of the extent of lymph node dissection on overall survival in patients treated for oral cavity squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6075-6075.	0.8	2
121	Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6077-6077.	0.8	0
122	Outcomes of elderly patients treated for oral cavity squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6076-6076.	0.8	0
123	Prognostic value of mid-treatment total lesion glycolysis in p16+ oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6047-6047.	0.8	0
124	p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3930-3938.	0.8	313
125	Radiotherapy for adenoid cystic carcinomas of the head and neck: clinical outcomes and patterns of failure. <i>Journal of Radiation Oncology</i> , 2014, 3, 49-56.	0.7	2
126	Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. <i>Radiotherapy and Oncology</i> , 2014, 110, 172-181.	0.3	585

#	ARTICLE	IF	CITATIONS
127	Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3365-3373.	0.8	449
128	Age Disparity in Palliative Radiation Therapy Among Patients With Advanced Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 224-230.	0.4	40
129	Galectin-1 links tumor hypoxia and radiotherapy. <i>Glycobiology</i> , 2014, 24, 921-925.	1.3	21
130	Commutability of the Epstein-Barr Virus WHO International Standard across Two Quantitative PCR Methods. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3802-3804.	1.8	36
131	Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response. <i>Clinical Cancer Research</i> , 2014, 20, 5558-5569.	3.2	64
132	Palliative Radiation Before Hospice: The Long and the Short of It. <i>Journal of Pain and Symptom Management</i> , 2014, 48, 1070-1079.	0.6	11
133	A Population-Based Comparative Effectiveness Study of Radiation Therapy Techniques in Stage III Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 872-884.	0.4	69
134	Imaging Features Associated With Disease Progression After Stereotactic Ablative Radiotherapy for Stage I Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 294-301.e3.	1.1	25
135	Accelerated Fractionation: The End of the Era of the Large, "One Size Fits All" Trial for Locally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 7-9.	0.4	1
136	The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience. <i>Journal of Clinical Oncology</i> , 2014, 32, 6025-6025.	0.8	2
137	Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. <i>Practical Radiation Oncology</i> , 2013, 3, 294-300.	1.1	19
138	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2208-2215.	3.2	149
139	p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). <i>Journal of Clinical Oncology</i> , 2013, 31, 6007-6007.	0.8	8
140	Seamless phase II/III trial design with survival and PRO endpoints for treatment selection: Case study of RTOG 1216. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS6099-TPS6099.	0.8	1
141	Racial inequality with radiation oncology referral and treatment in metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 470-470.	0.8	0
142	The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma. <i>PET Clinics</i> , 2012, 7, 381-394.	1.5	2
143	Evaluation of a metal artifact reduction technique in tonsillar cancer delineation. <i>Practical Radiation Oncology</i> , 2012, 2, 27-34.	1.1	9
144	Metabolic Tumor Volume is an Independent Prognostic Factor in Patients Treated Definitively for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 52-58.	1.1	83

#	ARTICLE	IF	CITATIONS
145	Palifermin Reduces Severe Mucositis in Definitive Chemoradiotherapy of Locally Advanced Head and Neck Cancer: A Randomized, Placebo-Controlled Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 2808-2814.	0.8	161
146	Validation of Lysyl Oxidase As a Prognostic Marker for Metastasis and Survival in Head and Neck Squamous Cell Carcinoma: Radiation Therapy Oncology Group Trial 90-03. <i>Journal of Clinical Oncology</i> , 2009, 27, 4281-4286.	0.8	72
147	Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. <i>Seminars in Radiation Oncology</i> , 2009, 19, 53-62.	1.0	16
148	Clinical biomarkers for hypoxia targeting. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 351-362.	2.7	70
149	In Vivo ¹ H Magnetic Resonance Spectroscopy of Lactate in Patients With Stage IV Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1151-1157.	0.4	26
150	Nasopharyngeal and Oropharyngeal Carcinomas: Target Delineation, Therapy Delivery and Stereotactic Boost Procedures with Intensity-Modulated/ Image-Guided Radiation Therapy. , 2007, 40, 208-231.		8
151	Expression and Prognostic Significance of a Panel of Tissue Hypoxia Markers in Head-and-Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 167-175.	0.4	111
152	Identifying and Targeting Hypoxia in Head and Neck Cancer: A Brief Overview of Current Approaches. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S56-S58.	0.4	19
153	Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. <i>Cancer</i> , 2006, 106, 1940-1949.	2.0	54
154	An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Nonâ€“Small Cell Lung Cancers. <i>Clinical Cancer Research</i> , 2006, 12, 1507-1514.	3.2	237
155	Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. <i>Journal of Thoracic Oncology</i> , 2006, 1, 802-9.	0.5	61
156	A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 5700-5707.	3.2	99
157	Galectin-1: A Link Between Tumor Hypoxia and Tumor Immune Privilege. <i>Journal of Clinical Oncology</i> , 2005, 23, 8932-8941.	0.8	233
158	Nonsurgical Therapy for Stages I and II Nonâ€“Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2005, 19, 237-261.	0.9	9
159	Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004). <i>Clinical Cancer Research</i> , 2004, 10, 5418-5424.	3.2	39
160	Hypoxic gene expression and metastasis. <i>Cancer and Metastasis Reviews</i> , 2004, 23, 293-310.	2.7	287
161	Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 375-383.	0.4	40
162	Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 1046-1054.	0.4	145

#	ARTICLE	IF	CITATIONS
163	Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. <i>Clinical Cancer Research</i> , 2003, 9, 4287-95.	3.2	31
164	Image-guided Hypo-fractionated Stereotactic Radiosurgery to Spinal Lesions. <i>Neurosurgery</i> , 2001, 49, 838-846.	0.6	298
165	Treatment of maxillary sinus carcinoma. <i>Cancer</i> , 1999, 86, 1700-1711.	2.0	93